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persistent HCV viremia. These studies and recently pub-
lished animal studies using the woodchuck model suggest 
that potent vaccines based on DNA or adenoviral vectored 
vaccination represent a rational way forward. However, 
combining these with drugs to suppress viral replication, 
alongside checkpoint inhibitors may be required to induce 
long-term immune control.
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The goals for HBV immunotherapy
There has been a recent resurgence in interest to develop 
novel strategies for therapeutic vaccination against hepati-
tis B virus (HBV) within both academia and pharma. This 
has primarily been driven by progress in the treatment of 
HBV and changing therapeutic goals and new tools for 
immunotherapy that include both viral vector strategies and 
molecular checkpoint inhibitors. A number of new drugs—
principally tenofovir and entecavir—that are safe and well 
tolerated with a high barrier to resistance have recently 
revolutionised the treatment of HBV [1–4]. However, with 
time it has been clear that the rates of HBV surface anti-
gen (HBsAg) loss and HBV “e” antigen (HBeAg) serocon-
version with these new therapies are very low so commit-
ting most patients to lifelong therapy [4, 5]. Furthermore, 
deploying lifelong therapies in resource-poor countries 
where the rates of HBV infection are the highest is rarely 
an option. In addition, there are emerging efforts to provide 
cure for HIV infection where some of the challenges paral-
lel those found in HBV including persisting viral genomes 
and lifelong therapies [6]. Together, these observations 
have provided a new impetus to identify new strategies to 
Abstract Currently, millions of people infected with 
hepatitis B virus (HBV) are committed to decades of treat-
ment with anti-viral therapy to control viral replication. 
However, new tools for immunotherapy that include both 
viral vectors and molecular checkpoint inhibitors are now 
available. This has led to a resurgence of interest in new 
strategies to develop immunotherapeutic strategies with the 
aim of inducing HBeAg seroconversion—an end-point that 
has been associated with a decrease in the rates of disease 
progression. Ultimately, a true cure will involve the elimi-
nation of covalently closed circular DNA which presents a 
greater challenge for immunotherapy. In this manuscript, I 
describe the development of immunotherapeutic strategies 
for HBV that are approaching or currently in clinical stud-
ies, and draw on observations of T cell function in natural 
infection supported by recent animal studies that may lead 
to additional rational vaccine strategies using checkpoint 
inhibitors. I also draw on our recent experience in develop-
ing potent vaccines for HCV prophylaxis based on simian 
adenoviral and MVA vectors used in prime–boost strate-
gies in both healthy volunteers and HCV infected patients. 
I have shown that the induction of T cell immune responses 
is markedly attenuated when administered to people with 
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cure HBV infection in patients currently receiving anti-
viral therapy.
Hope that immunotherapy may be a successful strategy 
for HBV comes from two observations; firstly, that robust 
adaptive immune responses are associated with viral con-
trol during acute HBV infection disease [7–9] and sec-
ondly, that in chronic HBV disease, spontaneous viral 
control with suppression of HBV DNA is associated with 
immune activation as evidenced by HBeAg seroconversion 
and liver inflammation with a flare in liver alanine transam-
inases (ALT) [10]. This is in contrast to human immuno-
deficiency virus (HIV) where persistent infection is almost 
always established after primary disease and to hepatitis C 
virus (HCV) infection, where immune control associated 
with spontaneous viral control is established is exceedingly 
rare once chronic disease is established.
The goals of immunotherapy are therefore twofold: (1) 
To induce HBeAg seroconversion in those on therapy; this 
end-point has been associated with lower rates of disease 
progression to cirrhosis and hepatocellular carcinoma, 
an increase in the rates of HBsAg seroconversion, and 
improved survival rates [11], and (2) more ambitiously, to 
provide a complete cure that would require the elimination 
of HBV covalently closed circular (ccc) DNA and therefore 
disappearance of its major expression product HBsAg with 
or without anti-HBs seroconversion.
A number of strategies are available for HBV immuno-
therapy. Some of these rely on emerging molecular tech-
nologies and include T cell receptor gene transfer and 
therapeutic antibody conjugates. However, these are techni-
cally challenging, carry significant safety concerns and are 
unlikely to be applicable in resource-poor settings. These 
technologies are discussed in detail by Bertoletti et al. in 
this issue. This article will therefore focus on new tech-
nologies that are close to the clinic, in particular, strategies 
to enhance adaptive immune responses, specifically T cells, 
and how these may be successfully combined with oral 
therapies and other adjuvants.
The rationale for HBV immunotherapeutic approaches
One of the key challenges for immunotherapy is the devel-
opment of strategies that enhance adaptive T cell responses 
in the setting of chronic high-level antigen exposure. A 
hallmark of persistent infection with HBV is a markedly 
attenuated or “exhausted” T cell response; low in magni-
tude, narrowly focused, poorly proliferative, and produc-
ing low levels of interleukin (IL)-2 [12, 13]. Advancing 
our understanding of the underlying mechanism for T cell 
attenuation is important for the development of rational 
therapeutic strategies. HBV infection is characterised by 
the persistent production of very high quantities of subviral 
HBsAg particles, and a secreted form of HBV core antigen 
named “e” antigen (HBeAg) that exceeds by a thousand-
fold or more the amount needed for assembly of complete 
HBV particles. However, the direct role of exposure to 
these antigens in attenuating T cell immunity is contro-
versial. Since HBV polymerase is not secreted in this way 
and T cell responses to polymerase are also attenuated, it is 
unlikely that these antigens are wholly responsible for the 
exhausted T cell profile observed.
Certainly, there is mounting evidence that T cell prim-
ing in a tolerating liver environment is likely to be critical, 
in addition to the premature death of HBV-specific T cells 
in the liver through proapoptotic protein Bcl2-interacting 
mediator (Bim)-dependent mechanisms [14, 15]. Further-
more, HBV has been shown to induce the liver enzyme 
arginase that depletes hepatic arginine resulting in T cells 
that are poorly proliferative [16]. A unifying hypothesis 
then is that HBV-specific T cells may be driven to apop-
tosis through the interplay between (1) high dose antigen, 
(2) the high expression of inhibitory signals, and (3) lack of 
co-stimulatory molecules and other inhibitor mechanisms 
within the liver. Immunotherapeutic strategies should seek 
then to target these factors and to induce functional anti-
viral T cells by vaccination.
HBV viral suppression
Taking these factors in turn, the suppression of HBV viral 
replication may be readily achieved using current oral 
therapies. This would serve two purposes—to reduce the 
chance of immunopathology in the context of immunother-
apeutic vaccination and possibly to facilitate the recovery 
of adaptive immune responses. Mouse models of lympho-
cytic choriomeningitis virus (LCMV) infection suggest that 
recovery of adaptive responses are best achieved in the set-
ting of low viral load [17], and in support of this, there is 
good evidence that HBV viral load suppression with oral 
anti-viral therapy is sometimes associated with immune 
activation and HBeAg seroconversion [18]. More typi-
cally, however, in the absence of HBeAg seroconversion, 
viral suppression with oral therapies is associated with a 
transient, early, and minimal increase in adaptive immune 
responses only [19]. Theoretically, it is plausible that inter-
mittent, low levels of viral replication are required to stimu-
late immune control of virus. It should be noted that whilst 
oral anti-virals reduce infectious virus through the inhibi-
tion of HBV reverse transcriptase, they have little effect on 
HBV antigen levels that are generated through transcription 
by RNA polymerase II, and no direct effect on HBV ccc 
DNA. Overall, since viral load suppression alone is gen-
erally insufficient to restore adaptive response, successful 
immunotherapy will need to be combined with additional 
strategies.
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Checkpoint inhibition
The high expression of inhibitory molecules on HBV-spe-
cific T cells is well described and provides some interesting 
molecular targets for additional immunotherapeutic strate-
gies including programmed cell death protein 1 (PD-1), 
cytotoxic T lymphocyte antigen 4 (CTLA-4), 2B4, T cell 
membrane protein 3 (Tim-3), Lymphocyte-activation gene 
3 (LAG-3), and their ligands—some of which are currently 
available for clinical use or in late stage development.
To date, these checkpoint inhibitors have largely been 
given to patients with advanced malignancy. CTLA-4 
has been linked to Bim expression, and the blocking of 
CTLA-4 in vitro has been linked to the expansion of HBV-
specific T cells. HBV viral load suppression with anti-viral 
therapy is not associated with a reduction in CTLA-4 or 
Bim levels on human HBV-specific T cells [15]. CTLA-4 
inhibitors are currently available in the clinic; ipilimumab 
(BMS) has been used successfully to treat patients with a 
range of malignancies including melanoma, prostate, and 
renal cancer, and was approved in 2011 by US regulators 
for the treatment of melanoma. However, this monoclonal 
antibody has been associated with immune-related side 
effects that include reversible colitis, rashes, and hepati-
tis [20]. In practice, it is unlikely that CTLA-4 checkpoint 
inhibitors will move into clinical studies of HBV in the 
near future since the safety profile of these are unaccepta-
ble in HBV patients who are otherwise well.
PD-1 and PD-1 ligand inhibitors are also in advanced 
development including three monoclonal antibodies, and 
three other drugs (reviewed in [21]) now in phase-I to 
phase III clinical trials. Therapeutic anti-PD-1 antibodies 
have been assessed in three chimpanzees and in humans 
with chronic HCV infection, but not in human studies of 
HBV infection. In one study of three chimpanzees chroni-
cally infected with HCV, pre-existing intrahepatic T cell 
responses and CD4+ and CD8+ HCV-specific T cells were 
restored, associated with a transient but substantial decline 
in HCV viral load showing for the first time that reversal 
of T cell tolerance induced by hepatotropic viruses is pos-
sible [22]. The anti-PD-1 monoclonal immunoglobulin G4 
(Nivolumab; BMS-936558) was subsequently assessed in 
54 patients with chronic HCV infection; five achieved a 
>0.5 log decline in HCV viral load, two achieved a viral 
load decline below the level of detection, and one patient 
became HCV undetectable. Immune-related side effects 
were seen in six patients, and in one patient, there was a 
grade 4 elevation in ALT associated with viral decline [23]. 
Overall, grade 3 and grade 4 adverse events have been seen 
in around 15 % of patients including deaths from pneumo-
nitis in oncology patients treated with nivolumab [24].
In spite of the significant adverse event profile, it is 
likely that anti-PD-1 immunotherapeutic strategies will be 
assessed in HBV phase-I studies in the short term. Clini-
cal experience in the use of anti-PD-1 strategies is growing, 
and overall the side effects are thought to be manageable. 
Furthermore, recent animal studies using a woodchuck 
model have shown promise for immunotherapeutic strate-
gies targeting the PD-1 pathway as an adjunct to vaccina-
tion; PD-1 blockade in combination with both entecavir 
and DNA vaccination increased virus-specific T cell func-
tion associated with anti-woodchuck hepatitis surface anti-
bodies and viral eradication in some animals [25]. LAG-3 
inhibitors are currently in phase-I clinical studies of solid 
tumours (ClinicalTrials.gov NCT01968109), whilst TIM-3 
inhibitors are in advanced pre-clinical development.
Lessons from studies of HBV immunotherapy
Previous attempts at therapeutic HBV vaccination have 
induced very low levels of T cells with minimal effects 
on viral suppression or HBV seroconversion events. Early 
efforts utilised HBsAg protein vaccines primarily induc-
ing antibodies with minimal effects in established infec-
tion [26–28]. HBV single and multi-epitope string vaccines 
have induced little immunogenicity, and these approaches 
are unlikely to give sufficient coverage across HBV geno-
types, or between people of distinct HLA types [29].
DNA vaccinations that encode small (S) and middle 
(preS2 and S) envelope proteins have also had limited suc-
cess; these have induced anti-preS2 antibodies and HBeAg 
seroconversion in the minority of HBV vaccines (2/10) 
associated with weak and transient T cell responses [30, 
31]. However, repeated vaccinations (n = 12) with DNA 
encoding S, preS1/S2, core, polymerase and X proteins 
with genetically adjuvanted IL-12 and oral anti-virals 
induced a multi-specific T cell response, sustained viral 
suppression, and HBeAg seroconversion in 6/12 patients 
[32, 33]. A recent pilot study of 36 patients with chronic 
HBV infection used electroporated DNA encoding HBV 
middle S protein with an IL-12/IFN gamma fusion pro-
tein given with lamivudine. This was associated with the 
generation of T cell immune responses with a reduction in 
HBV viral load in some people [33]. However, DNA vac-
cine strategies that require painful electroporation or multi-
ple injections to generate significant immune responses are 
unlikely to be widely clinically applicable. For these rea-
sons, heterologous prime/boost vaccination strategies using 
viral vectors have been assessed as an alternative strat-
egy. DNA prime/MVA boost vaccine encoding S, preS1/
S2 showed promise in a chimpanzee study [34]. However, 
when the same vaccine was assessed in a clinical study in 
Gambia given with or without lamivudine, there was no T 
cell induction or reduction in viremia [35]. The reasons for 
this may relate to the fact that the vaccine contained S and 
preS immunogens only. However, strategies that reduce 
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HBV viral load with drug therapy before DNA prime/Ad 
boost encoding HBV core has shown real promise in the 
HBV woodchuck model; this strategy was able to induce 
a robust CD4+ and CD8+ T cell response associated 
with control of viremia and HBsAg seroconversion [36]. 
Transgene, a French biopharmaceutical company develop-
ing viral vectored approaches for the treatment of infec-
tious disease, is planning to assess non-replicative Ad5 
vectors (TG1050) encoding multiple HBV antigens (Core, 
Polymerase and Envelope) from genotype D HBV in China 
in late 2014 (press-release July 2014).
Innate immune stimulation
One of the advantages of a virally vectored vaccine is 
that the vectors themselves will induce innate immune 
responses. This may be important given the observation 
that innate immune stimulation alone may be associated 
with HBV viral control though mechanisms that are cur-
rently not clear. For example, the administration of Granu-
locyte–macrophage colony-stimulating factor (GM–CSF) 
has been associated with HBV DNA and/or HBeAg loss in 
up to 60 % of treated patients [37, 38]. Furthermore, a com-
parison of two consecutive studies assessing an antigen–
antibody (HBsAg–HBIG) immunogenic complex thera-
peutic vaccine candidate with alum as adjuvant and alum 
alone as placebo suggested that increasing the frequency of 
dosing with alum alone could increase the rates of HBeAg 
seroconversion [39, 40]. Validation of this observation, 
however, would require a head-to-head comparison of the 
effects of the frequency of alum dosing within the same 
study. Additional strategies that aim to block regulatory or 
induce stimulatory cytokines should also been considered. 
IL-10 levels are elevated during chronic disease, and in 
vitro IL-10 blockade can restore HBV-specific T cell func-
tionality [41]. However, in acute disease, elevated plasma-
IL-10 levels have been associated with the attenuation of T 
cell immunity during acute infection [42] and with hepatic 
inflammatory flares during acute disease suggesting that 
in this setting, IL-10 potentially regulates immunopathol-
ogy. Together, these studies highlight the critical role 
that IL-10 may play in balancing immunopathology with 
persistent viremia (reviewed in Couper KN 2008 [43]). 
Although IL-10 blockade facilitates DNA vaccine-induced 
T cell responses and enhances clearance of persistent 
LCMV infection [44], it is unlikely that IL-10 blockade 
will move into human studies of HBV as an immunothera-
peutic or as an adjuvant in the short/medium term, given 
the risks of immunopathology. IL-12 is also a candidate as 
this has recently been shown in vitro to enhance the cyto-
toxicity, polyfunctionality, and multispecificity of HBV-
specific T cells and combining IL-12 with blockade of the 
PD-1 pathway further increased the functionality of CD8+ 
HBV-specific T cells [45]. Recombinant human IL-12 
has been used in cancer immunotherapy, and whilst anti-
tumour effects have been limited, IL-12 has been shown 
to be well tolerated and to induce cellular immunity [46]. 
Genetic HBV vaccines that encode IL-12 have shown 
promise as discussed above [32].
Lessons from HCV immunotherapy‑viral vectored 
technologies
The recent development of viral vectored technology to 
deliver immunogens has been a major step forward in the 
field, with the capacity now to generate unprecedented lev-
els of T cells in healthy volunteers. Earlier work from the 
Merck HIV and Oxford malaria vaccine programs used 
replicative defective adenoviral vectors to prime T cell 
responses [47]. However, one of the limitations of this tech-
nology is the presence of pre-existing anti-vector immunity 
that may attenuate vaccine responses. However, the use of 
chimpanzee adenoviruses, to which humans have no prior 
exposure, can overcome this issue [48].
Important lessons can be learnt from our recent stud-
ies of immunotherapy in HCV infection using chimpanzee 
adenovirus that may also now be applicable to immuno-
therapy for HBV. In collaboration with an SME Okairos 
(Rome, Italy), we have recently shown that vaccination 
with adenoviral vectors derived from chimpanzee (AdCh3) 
and rare human adenovirus serotypes (AdHu6) encoding 
the non-structural (NS) proteins of HCV induce a very high 
magnitude of durable T cell responses, with a broad speci-
ficity in healthy volunteers [49]. The key observations that 
viral load is inversely correlated with CD8+ T cell func-
tion in chronic HBV disease [50], the association of class-
II alleles with viral persistence [51], and that CD4+ and 
CD8+ blocking experiments are associated with viral per-
sistence in chimpanzees [8] show that both T cell subsets 
will need to be induced during immunotherapy.
Our recent data show that heterologous boosting fol-
lowing adenoviral prime with modified vaccinia Ankara 
(MVA) encoding the same immunogen further enhances 
both CD8+ and CD4+ T cell subsets in healthy individu-
als [49]. This strategy shows real promise as a prophylac-
tic vaccine strategy and is now in efficacy testing in Bal-
timore in a large population of intravenous drug users at a 
high risk of exposure to HCV infection (ClinicalTrials.gov 
NCT01436357).
We have also applied the same vaccine strategy to 
patients with chronic HCV genotype-1 infection to assess 
for the first time, the capacity of a potent T cell vaccine 
to restore adaptive immunity in chronic HCV viremia. 
Vaccination was performed in the setting of a high HCV 
viral load, and in the setting of a suppressed viral load 2 
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or 14 weeks into interferon and ribavirin therapy. Overall, 
we were able to show that T cells were induced to very 
high levels in a minority of patients, irrespective of viral 
suppression [52]. However, in those patients, analysis of 
the host circulating HCV viral sequence showed significant 
variation in epitopes targeted by vaccine-induced T cells, in 
comparison with the vaccine immunogen [53]. Overall, we 
learnt three important lessons from these studies. Firstly, 
viral load suppression and vaccination with a demonstra-
bly potent vaccine may not be sufficient to restore adap-
tive immune responses. Secondly, vaccine-induced T cell 
responses cannot be interpreted without a detailed knowl-
edge of the sequence of the endogenous virus in vaccinees, 
and thirdly, it is not possible to assess the potency of a vac-
cine applied in patients with chronic infection if this vac-
cine has not been first assessed in healthy volunteers.
Each of these lessons may now usefully be applied to 
vaccine studies of immunotherapy in HBV infection—
though there are a number of important differences. In the 
HCV immunotherapy studies described above, the assess-
ment of the effect of viral load suppression on T cell res-
toration is confounded by the fact that interferon (IFN) 
therapy is known to have immunosuppressive and anti-
proliferative effects [54]. A similar study in HBV could use 
HBV anti-viral suppression free from these effects. Also 
the viral diversity of HBV is much reduced compared with 
HCV, so that the capacity of a vaccine to induce T cells that 
do not cross-react with circulating virus is reduced. Never-
theless, HBV viral sequence analysis should be employed 
for the meaningful interpretation of vaccine-induced T 
cell responses. And finally, new HBV vaccines should be 
assessed in healthy people first so that the potency of the 
vaccine is established. In the generation of a successful 
HBV immunotherapeutic vaccine, the design of the HBV 
immunogen will clearly be critical. Since adenoviral vec-
tors can encode large immunogens (>1,500 amino acids) 
HBV surface, core and polymerase antigens could be 
encoded in a first generation HBV immunotherapeutic vac-
cine (see also the article by Kosinska et al. in this issue).
In the HCV studies, we saw no conclusive evidence of 
immunopathology in vaccinated subjects. This is not sur-
prising given the fact that vaccine-induced T cells rarely 
targeted endogenous virus. Furthermore, in HCV, only 4 % 
of hepatocytes are thought to be infected [55], and severe 
hepatic inflammation associated with adaptive immunity is 
rarely observed in natural HCV infection. The same may 
not be true in HBV where the majority of hepatocytes are 
infected in chronic disease and where fulminant liver fail-
ure is associated with adaptive immune responses during 
primary infection, during seroconversion events in chronic 
disease, and during immune reconstitution after reactiva-
tion of occult HBV infection. The co-administration of oral 
anti-virals reducing HBV load should significantly reduce 
the risks of serious immunopathology as new vectors are 
given to patients for the first time. Thus, immunotherapeu-
tic strategies for HBV will need to tread a careful line aim-
ing to induce immune events associated with HBV sero-
conversion without inducing severe hepatic inflammation.
The repeated administration of attenuated poxvirus as viral 
vectors has been assessed by Transgene (France). MVA viral 
vectors encoding HCV NS proteins (TG4040) were adminis-
tered repeatedly (n = 6) in patients with chronic HCV infec-
tion associated with a transient decline in HCV RNA levels 
in some people [56]. In a phase-II study, this regimen was 
associated with early viral clearance, but not a statistically 
significant increase in sustained virological response [57]. 
Whilst this approach was able to induce HCV-specific T cells, 
these studies did not evaluate the capacity of vaccine-induced 
T cells to target endogenous virus in patients.
cccDNA eradication
The elimination of nuclear cccDNA is required if HBV is 
to be cured, and this represents a major challenge for HBV 
immunotherapy. The issue of HBV cccDNA eradication 
is not easily addressed since cccDNA infects 40–100 % 
of hepatocytes and has in most cases a lifespan as long as 
the hepatocyte. It has long been known that the adminis-
tration of IFN-α therapy in patients with chronic HBV 
infection, and particularly those with elevated transami-
nases at baseline may be associated with cure in a minority 
of people. HBV cure is defined as HBsAg loss and anti-
HBs seroconversion which is believed to indicate eradica-
tion or inactivation of cccDNA. Furthermore, there is an 
increased incidence of cure in these patients that continues 
for some years after the cessation of therapy. It is evident 
that innate mechanisms are capable of cccDNA eradica-
tion. Supporting studies in animal models of HBV, primary 
hepatocytes, and human liver needle biopsies have demon-
strated that interferon-α and lymphotoxin-β receptor activa-
tion may upregulate nuclear deaminases (APOBEC3A and 
APOBEC3B) mediated by HBV core resulting in cccDNA 
degradation that prevents HBV reactivation [58].
Recent studies sponsored by Gilead sciences have 
developed a selective oral TLR-7 agonist (GS-9620) with 
the aim of curing chronic HBV infection. A study in three 
chimpanzees with chronic infection showed that this com-
pound was able to suppress viral load by >1 log for some 
months, associated with the stimulation of interferon-α 
and interferon stimulated genes, chemokines, and natural 
killer cells. An increase in hepatocyte apoptosis was associ-
ated with a fall in serum HBsAg, HBeAg, and HBV anti-
gen positive hepatocytes. [59] Gilead has since moved into 
human studies. Three clinical trials were started in 2013 
people with chronic hepatitis B. Two of the studies have 
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been completed and results are pending. The third study is 
on-going (ClinicalTrial.gov NCT01590654).
Studies on HIV that aim to cure patients are hoping to 
induce reactivation of latently infected cells using histone 
deacetylases inhibitors (HDACi) to induce viral transcrip-
tion in latently infected cells in patients on HAART, in con-
junction with immunotherapeutic approaches [60]. Simi-
lar strategies may be developed for HBV immunotherapy. 
However, the replication-competent HBV cccDNA is not 
integrated in the host genome and may not be activated by 
HDACi, and whilst the integrated forms of HBV DNA may 
be silenced, these are not responsible for the generation of 
infectious virus. The success of any approach that sought 
to eliminate cccDNA would most likely rely on the co-
administration of oral HBV anti-virals or HBV viral entry 
inhibitors targeting HBV receptors [61, 62] to prevent the 
replenishment of the latently infected viral pool.
Conclusion
In summary, new therapeutic strategies that aim to induce 
long-term HBV immune control or provide a complete 
cure through the elimination of cccDNA will be assessed in 
phase-I/II clinical studies in the short/medium term. These 
are likely to proceed cautiously, and in a step-wise fashion 
in patients without significant liver fibrosis and in patients 
where viral load is suppressed with oral anti-virals therapy. 
Highly immunogenic vaccines based on adenoviral and 
MVA vectors used in prime–boost strategies are now avail-
able for clinical studies, and the use of simian adenoviruses 
overcomes the issue of pre-existing vector immunity. The 
choice of immunogen will be critical but will to some extent 
require a “test and see” approach in humans. Nevertheless, 
it would seem prudent to include polymerase, core, and pos-
sibly preS/S antigens in a first generation vaccine. Our own 
data from immunotherapeutic studies of HCV suggest that 
potent vaccines alone may not be sufficient to restore the 
function of T cells that have been exposed to antigen for 
many years and additional strategies such as the co-admin-
istration of checkpoint inhibitors and adjuvants that aim to 
induce innate immunity will also be required. New platforms 
in viral vectored technology and molecular approaches mean 
that immunotherapy for HBV that seeks to control and/or 
cure HBV replication is now a real possibility.
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